- Home
- CARE vs ZURA Comparison
CARE vs ZURA Comparison
Compare CARE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CARE | ZURA |
|---|---|---|
| Founded | 1974 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.1M | 521.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CARE | ZURA |
|---|---|---|
| Price | $24.06 | $5.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $25.00 | $13.00 |
| AVG Volume (30 Days) | 277.4K | ★ 601.3K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | $12.50 | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $14.58 | $0.99 |
| 52 Week High | $24.86 | $7.25 |
Technical Indicators
Market Signals| Indicator | CARE | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 39.98 |
| Support Level | $19.49 | $5.35 |
| Resistance Level | $24.86 | $5.75 |
| Average True Range (ATR) | 0.49 | 0.34 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 73.46 | 6.25 |
Price Performance
Historical ComparisonAbout CARE Carter Bankshares Inc.
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.